Actively Recruiting
Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy
Led by Linda Cendales · Updated on 2026-04-09
50
Participants Needed
1
Research Sites
691 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to determine the safety and efficacy of hand transplantation as a treatment for patients with loss of limb below the elbow, The study will focus on patients who have had loss of limb. The primary endpoint is the ability to use the tranplanted limb in activities of daily living at 18 months following transplantation measured by a quantitative functional test. Study activities include several study visits over 18 months and include; demographics, medical history, vital signs, psychosocial evaluation, urine, blood test, chest x-ray, bone density scans, and biopsies. Subjects who are 18-65 and willing to travel to site and have loss of limb will be included in study evaluation. Risks of the study include risk of rejection and infection after being transplanted. Additional risk are associated with procedures that include blood draws, biopsies, x-rays, and potential loss of confidentiality. All patient data will be kept electronically and in accordance with the requirements of Duke University. In addition to the experimental data, this database includes recipient and donor demographics and transplant relevant medical history, range of motion, sensation, and immunosuppressive medications. Data will be recorded and reported in accordance with the standards required by the United Network for Organ Sharing (UNOS).
CONDITIONS
Official Title
Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 to 65 years with loss of limb
- Willingness and legal ability to give informed consent
- Willingness to travel to study site for protocol-specific samples or ability to send samples via overnight mail
You will not qualify if you...
- Any condition preventing regular follow-up
- Any condition that increases risk or confounds data interpretation
- Any active malignancy or history of malignancy or lymphoma
- Inability or unwillingness to comply with protocol monitoring, therapy, or immunodeficiency syndromes
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Duke University Medical Center
Durham, North Carolina, United States, 27710
Actively Recruiting
Research Team
L
Linda Cendales, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here